--- title: "TherapeuticsMD Inc. Stock Outperforms Competitors On Strong Trading Day" type: "News" locale: "en" url: "https://longbridge.com/en/news/287123284.md" description: "TherapeuticsMD Inc. (TXMD) shares rose 1.96% to $2.08 on a strong trading day, marking the fourth consecutive day of gains. The NASDAQ Composite Index increased by 1.54%, while the Dow Jones Industrial Average rose 1.31%. TXMD remains 29.49% below its 52-week high of $2.95. In contrast, competitor AbbVie Inc. (ABBV) fell 0.68% to $212.30. Trading volume was below the 50-day average." datetime: "2026-05-20T21:29:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287123284.md) - [en](https://longbridge.com/en/news/287123284.md) - [zh-HK](https://longbridge.com/zh-HK/news/287123284.md) --- # TherapeuticsMD Inc. Stock Outperforms Competitors On Strong Trading Day This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of TherapeuticsMD Inc. (TXMD) rallied 1.96% to $2.08 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 1.54% to 26,270.36 and the Dow Jones Industrial Average rising 1.31% to 50,009.35. This was the stock's fourth consecutive day of gains. TherapeuticsMD Inc. closed 29.49% short of its 52-week high of $2.95, which the company reached on January 27th. The stock outperformed some of its competitors Wednesday, as AbbVie Inc. (ABBV) fell 0.68% to $212.30. Trading volume (10,068) remained 11,924 below its 50-day average volume of 21,992. Data source: Dow Jones Market Data, FactSet. Data compiled May 20, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 05-20-26 1729ET ### Related Stocks - [TXMD.US](https://longbridge.com/en/quote/TXMD.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md) - [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) ## Related News & Research - [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)